Skip to main content
رجوع
Watch Compare

CUMBERLAND PHARMACEUTICALS INC

جودة البيانات: 100%
CPIX
Nasdaq Manufacturing Chemicals
KWD 3.09
▼ KWD 0.02 (-0.64%)
القيمة السوقية: 47.26 M
السعر
KWD 3.16
القيمة السوقية
47.26 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Revenue grew 5.47% annually over 5 years — modest growth
Generating 4.83 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12.10%
Capital efficient — spends only 0.22% of revenue on capex

النمو

Revenue Growth (5Y)
5.47%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)17.57%
Earnings (1Y)N/A
FCF Growth (3Y)-8.80%

الجودة

Return on Equity
-10.48%
أعلى من متوسط القطاع (-53.34%)
ROIC-5.16%
Net Margin-6.37%
Op. Margin-6.27%

الأمان

Debt / Equity
N/A
Current Ratio1.23
Interest Coverage-5.63

التقييم

PE (TTM)
-16.66
أقل من متوسط القطاع (-1.47)
P/B Ratio1.81
EV/EBITDA23.70
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -16.7 -1.5
P/B 1.8 1.6
ROE % -10.5 -53.3
Net Margin % -6.4 -41.5
Rev Growth 5Y % 5.5 1.8
D/E — 0.3

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

لا تتوفر تقديرات مستقبلية

مفاجآت الأرباح

آخر 4 أرباع
الربع EPS المقدر EPS الفعلي المفاجأة
Q22021 -KWD 0.07 KWD 0.00 +98.4%
Q12021 -KWD 0.07 KWD 0.07 +200.0%
Q42020 -KWD 0.01 KWD 0.01 +200.0%
Q32020 -KWD 0.07 KWD 0.02 +128.6%

ETFs Holding This Stock

BRUSX BRUSX
0.60% weight
BRSIX BRSIX
0.22% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 17.57% Revenue Growth (3Y) 6.10%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.47% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 44.52 M Net Income (TTM) -2.84 M
ROE -10.48% ROA -4.24%
Gross Margin N/A Operating Margin -6.27%
Net Margin -6.37% Free Cash Flow (TTM) 4.83 M
ROIC -5.16% FCF Growth (3Y) -8.80%
Safety
Debt / Equity N/A Current Ratio 1.23
Interest Coverage -5.63 Asset Turnover 0.67
Working Capital 5.63 M Tangible Book Value 10.20 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -16.66 Forward P/E N/A
P/B Ratio 1.81 P/S Ratio 1.06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 23.70 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 10.23%
Market Cap 47.26 M Enterprise Value 32.07 M
Per Share
EPS (Diluted TTM) -0.19 Revenue / Share 2.98
FCF / Share 0.32 OCF / Share 0.33
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.22% FCF Conversion -170.47%
SBC-Adj. FCF 4.52 M Growth Momentum 12.10

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44.52 M 37.87 M 39.55 M 42.01 M 35.99 M
Net Income -2.84 M -6.48 M -6.28 M -5.57 M -3.51 M
EPS (Diluted) -0.19 -0.46 -0.44 -0.38 -0.24
Gross Profit — — — — —
Operating Income -2.79 M -6.43 M -9.55 M -5.70 M -7.68 M
EBITDA — — — — —
R&D Expenses 5.57 M 4.82 M 5.83 M 6.69 M 5.68 M
SG&A Expenses — — — — —
D&A 4.15 M 4.90 M 4.94 M 5.33 M 4.61 M
Interest Expense 495,990.0 605,508.0 667,861.0 585,995.0 98,031.0
Income Tax 40,256.0 -22,669.0 45,769.0 68,850.0 34,891.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 76.82 M 75.58 M 81.78 M 92.93 M 84.46 M
Total Liabilities 52.28 M 53.04 M 52.52 M 56.95 M 41.86 M
Shareholders' Equity 24.88 M 22.85 M 29.60 M 36.27 M 42.81 M
Total Debt — — — — —
Cash & Equivalents 11.44 M 17.96 M 18.32 M 19.76 M 27.04 M
Current Assets 37.06 M 36.45 M 35.71 M 45.87 M 45.69 M
Current Liabilities 36.74 M 31.62 M 27.98 M 28.58 M 19.28 M